Citadel Advisors’s ImmunoCellular Therapeutics Ltd. IMUC.WS Stock Holding History

Citadel Advisors’s Portfolio IMUC.WS Stock Details IMUC.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-14,139	Closed	-$1K	–	10287
2018 Q3	$1K	Buy	+14,139	New	+$342	﹤0.01%	9138

Citadel Advisors's IMUC.WS Position: Q4 2018 in Review

Citadel Advisors sold out of ImmunoCellular Therapeutics Ltd. (IMUC.WS) in Q4 2018, closing a stake of 14,139 shares — an estimated $1K sold.

Citadel Advisors first reported a position in IMUC.WS in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 0 funds tracked by Wall St. Rank hold IMUC.WS as of Q4 2018.

Citadel Advisors reported no remaining ImmunoCellular Therapeutics Ltd. position as of Q4 2018 after selling out during the quarter.
Citadel Advisors sold 14,139 ImmunoCellular Therapeutics Ltd. shares in Q4 2018, an estimated $1K.
Citadel Advisors first reported a position in ImmunoCellular Therapeutics Ltd. in Q3 2018 and held it in 1 quarter.
Citadel Advisors's ImmunoCellular Therapeutics Ltd. position peaked at $1K in Q3 2018.
0 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics Ltd. as of Q4 2018.

Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.